Sinclair IS Pharma and Invida Successfully Launch Leading Dermatology Brands Atopiclair and Papulex Across Seven Asia-Pacific Markets  
9/29/2011 10:47:08 AM

LONDON--(BUSINESS WIRE)--Sinclair IS Pharma Plc ("Sinclair IS" or “the Company”: SPH:L), the international specialty pharmaceutical company, and Invida Holdings Private Limited (“Invida”), a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets. Atopiclair, a treatment for atopic dermatitis, has been launched in Hong Kong, Malaysia, Singapore and India, and Papulex, for management and maintenance of mild to moderate acne, has been launched in Taiwan, India and Hong Kong. Launches are scheduled in a further four countries by calendar year-end. In addition, in May 2011 Invida re-launched Flammazine and Flammacerium, sterile creams for the prevention and treatment of infections in burns and topical wound infections in the Philippines.